...
首页> 外文期刊>Blood: The Journal of the American Society of Hematology >Identification and expansion of highly suppressive CD8 +FoxP3 + regulatory T cells after experimental allogeneic bone marrow transplantation
【24h】

Identification and expansion of highly suppressive CD8 +FoxP3 + regulatory T cells after experimental allogeneic bone marrow transplantation

机译:实验性同种异体骨髓移植后高抑制性CD8 + FoxP3 +调节性T细胞的鉴定和扩增

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

FoxP3 + confers suppressive properties and is confined to regulatory T cells (T reg) that potently inhibit autoreactive immune responses. In the transplant setting, natural CD4 + T reg are critical in controlling alloreactivity and the establishment of tolerance. We now identify an important CD8 + population of FoxP3 + T reg that convert from CD8 + conventional donor T cells after allogeneic but not syngeneic bone marrow transplantation. These CD8 + T reg undergo conversion in the mesenteric lymph nodes under the influence of recipient dendritic cells and TGF-β. Importantly, this population is as important for protection from GVHD as the well-studied natural CD4 +FoxP3 + population and is more potent in exerting class I-restricted and antigen-specific suppression in vitro and in vivo. Critically, CD8 +FoxP3 + T reg are exquisitely sensitive to inhibition by cyclosporine but can be massively and specifically expanded in vivo to prevent GVHD by coadministering rapamycin and IL-2 antibody complexes. CD8 +FoxP3 + T reg thus represent a new regulatory population with considerable potential to preferentially subvert MHC class I-restricted T-cell responses after bone marrow transplantation.
机译:FoxP3 +具有抑制作用,并局限于有效抑制自身反应性免疫应答的调节性T细胞(T reg)。在移植环境中,天然CD4 + T reg对于控制同种反应性和建立耐受性至关重要。现在,我们确定同种异体而非同基因骨髓移植后从CD8 +传统供体T细胞转换而来的重要CD8 + FoxP3 + T reg种群。这些CD8 + T reg在受体树突状细胞和TGF-β的影响下在肠系膜淋巴结中进行转化。重要的是,该种群与研究良好的天然CD4 + FoxP3 +种群一样,对于预防GVHD同样重要,并且在体外和体内发挥I类限制性和抗原特异性抑制作用更为有效。至关重要的是,CD8 + FoxP3 + T reg对环孢菌素的抑制非常敏感,但可以通过联合使用雷帕霉素和IL-2抗体复合物在体内大量特异性地扩增,从而预防GVHD。因此,CD8 + FoxP3 + T reg代表着一个新的调节人群,在骨髓移植后具有相当大的潜力优先颠覆MHC I类限制的T细胞反应。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号